Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class IHDAC profiles between epithelial and stromal cells
Waltregny, David; North, Brian; Van Mellaert, Franket al.
2004 • In European Journal of Histochemistry, 48 (3, Jul-Sep), p. 273-290
[en] Histone deacetylases (HDACs) represent a large family of enzymes identified as key regulators of nucleosomal histone acetylation, a major epigenetic event that controls eukaryotic gene transcription. Inappropriate deacetylation mediated by HDACs has been associated with profound alterations in cellular biology. We have thus hypothesized that an altered HDAC expression may favor cancer development/progression. To test this possibility, we have sought to screen the expression profiles of several class I and class 11 HDACs (HDAC1-8) in DU-145, PC-3 and LNCaP human prostate cancer cell lines as well as in matched malignant and nonmalignant prostate tissues by use of real time RT-PCR, immunoblot and immunohistochemistry. All HDAC transcripts tested were detected at various levels in all prostate cancer cell lines and tissue samples analyzed. In prostate tissues, the abundance of HDAC1 protein, which was exclusively expressed in the cell nucleus, was similar in normal and malignant epithelial cells, but was usually lower in stromal cells. Unexpectedly, HDAC8, another class I HDAC, was not detected in epithelial cells but was uniquely expressed in the cytoplasm of stromal cells, HDAC5, a class II HDAC involved in myogenesis, was not detected in the tissues. Altogether, our findings indicate that epithelial and stromal cells exhibit distinct class I HDAC expression profiles, and the abundance of HDAC1 is not altered in human prostate cancer. In addition, our observations are the first to demonstrate the prominently cytosolic distribution of a class I HDAC, HDAC8.
Waltregny, David ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Labo de recherche sur les métastases
North, Brian
Van Mellaert, Frank
de Leval, Jean ; Université de Liège - ULiège > Département des sciences cliniques > Urologie
Verdin, Eric
Castronovo, Vincenzo ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire
Language :
English
Title :
Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class IHDAC profiles between epithelial and stromal cells
Alland L, Muhle R, Hou H Jr, Potes J, Chin L, Schreiber-Agus Net al. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 1997;38749-55.
Bartl S, Taplick J, Lagger G, Khier H, Kuchler K, Seiser C. Identification of mouse histone deacetylase 1 as a growth factor- inducible gene. Mol Cell Biol 1997;17:5033-43.
Buggy JJ, Sideris ML, Mak P, Lorimer DD, McIntosh B, Clark JM. Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem J 2000;350:199-205.
Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-5170.
Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res 2001;7:962-970.
Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000;184:1-16.
Dangond F, Henriksson M, Zardo G, Caiafa P, Ekstrom TJ, Gray SG. Differential expression of class I HDACs: roles of cell density and cell cycle. Int J Oncol 2001;19:773-7.
De Ruijter AJ, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-49.
Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002;21427-36.
Ellerhorst J, Nguyen T, Cooper DN, Estrov Y, Lotan D, Lotan R. Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin-1. Int J Oncol 1999;14:225-32.
Emiliani S, Fischle W, Van Lint C, Al-Abed Y, Verdin E. Characterization of a human RPD3 ortholog, HDAC3. Proc Natl Acad Sci USA 1998;95:2795-800.
Fink L, Seeger W, Ermert L, Hanze J, Stahl U, Grimminger F, et al. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 1998;4:1329-33.
Fischer DD, Cai R, Bhatia U, Asselbergs FA, Song C, Terry R, et al. Isolation and Characterization of a novel class II Histone Deacetylase, HDAC10. J Biol Chem 2002;277:6656-66.
Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 2002;9:45-57.
Frye RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 1999;260:273-9.
Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 2002;277:25748-55.
Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. J Cell Biochem 1998;69:271-81.
Gray SG, Ekstrom TJ. Effects of cell density and trichostatin A on the expression of HDAC1 and p57Kip2 in Hep 3B cells. Biochem Biophys Res Commun 1998;245:423-7.
Gray SG, Ekstrom TJ.The human histone deacetylase family. Exp Cell Res 2001;262:75-83.
Grozinger CM, Hassig CA, Schreiber SL.Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci USA 1999;96:4868-73.
Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52.
Guardiola AR, Yao TP. Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10. J Biol Chem 2002; 277: 33506.
Halgunset J, Lamvik T, Espevik T. Butyrate effects on growth, morphology, and fibronectin production in PC-3 prostatic carcinoma cells. Prostate 1988;12:65-77.
Halkidou K, Cook S, Leung HY, Neal DE, Robson CN. Nuclear accumulation of histone deacetylase 4 coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol 2004; in press.
Hu E, Chen Z, Fredrickson T, Zhu Y, Kirkpatrick R, Zhang GF, Johanson K, et al. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem 2000;275:15254-64.
Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002; 417:455-8.
Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD- dependent histone deacetylase. Nature 2000;403:795-800.
Kao HY, Downes M, Ordentlich P, Evans RM. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev 2000;14:55-66.
Kao HY, Lee CH, Komarov A, Han CC, Evans RM. Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J Biol Chem 2002;277:187-93.
Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7:437-43.
Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 1999;18:2461-70.
Knoepfler PS, Eisenman RN. Sin meets NuRD and other tails of repression. Cell 1999;99:447-50.
Koipally J, Renold A, Kim J, Georgopoulos K. Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. Embo J 1999;18:3090-100.
Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target.Trends Endocrinol Metab 2001;12:294-300.
Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. British Journal of Cancer 2004:535-41.
Kwon HJ, Owa T, Hassig CA, Shimada J, Schreiber SL. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc Natl Acad Sci USA 1998;95:3356-61.
Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. Embo J 2002;21:2383-96.
Lu J, McKinsey TA, Nicol RL, Olson EN. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci U S A 2000a;97:4070-5.
Lu J, McKinsey TA, Zhang CL, Olson EN. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol Cell 2000b;6:233-44.
Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 2001;107:137-48.
Maier S, Reich E, Martin R, Bachem M, Altug V, Hautmann RE, et al. Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines. Int J Cancer 2000;88:245-51.
Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-6.
Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, et al. In vivo destabilization of dynamic micro-tubules by HDAC6-mediated deacetylation. Embo J 2002;21:6820-31.
Megee PC, Morgan BA, Mittman BA, Smith MM. Genetic analysis of histone H4: essential role of lysines subject to reversible acetylation. Science 1990;247:841-5.
Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997;89:373-80.
Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyl-transferase in human prostate cancer. Biochem Biophys Res Commun 2001;287:705-13.
Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 2001;61:1477-85.
Rennie PS, Nelson CC. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev 1998;17:401-9.
Schwer B, North BJ, Frye RA, Ott M,Verdin E.The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol 2002;158:647-57.
Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-75.
Suenaga M, Soda H, Oka M,Yamaguchi A, Nakatomi K, Shiozawa K, et al. Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. Int J Cancer 2002;97:621-5.
Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacety-lase related to the yeast transcriptional regulator Rpd3p. Science 1996;272:408-11.
Tong JJ, Liu J, Bertos NR,Yang XJ. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res 2002;30:1114-23.
Van den Wyngaert I, de Vries W, Kremer A, Neefs J, Verhasselt P, Luyten WH et al. Cloning and characterization of human histone deacetylase 8. FEBS Lett 2000;478:77-83.
Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-59.
Verdel A, Khochbin S. Identification of a new family of higher eukary-otic histone deacetylases. Coordinate expression of differentiation- dependent chromatin modifiers. J Biol Chem 1999;274:2440-5.
Walls R,Thibault A, Liu L,Wood C, Kozlowski JM, Figg WD, et al.The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. Prostate 1996;29:177-82.
Wheeler TM, Lebovitz RM. Fresh tissue harvest for research from prostatectomy specimens. Prostate 1994;25:274-9.
Yang WM, Tsai SC, Wen YD, Fejer G, Seto E. Functional domains of histone deacetylase-3. J Biol Chem 2002;277:9447-54.
Yang WM, Yao YL, Sun JM, Davie JR, Seto E. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J Biol Chem 1997; 272: 28001-7.
Zhou Q, Melkoumian ZK, Lucktong A, Moniwa M, Davie JR, Strobl JS. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of his-tone deacetylase-1. J Biol Chem 2000;275:35256-63.
Zhou X, Marks PA, Rifkind RA, Richon VM. Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci USA 2001;98:10572-7.
